Your Current Position: NEWS > Company News
-
2022-12-22On Dec. 21, 2022, the Investigational New Drug (IND) Application of V01, the first oncolytic vaccinia virus product independently innovated by Converd, was accepted by Center For Drug Evaluation, NMPA.
-
【Company News】 Latest clinical findings of the ConVerd's subsidiary self-develped NKG2D-CAR-NK published in Molecular Therapy2019-09-21The latest results of a NKG2D-CAR-NK's clinical stuy, conducted by ConVerd's subsidiary and a team led by Hu Xv who is the president of the 3rd hospital of Guangzhou Medical University, were publishe in the journal, Molecular Therapy.
-
2019-04-12Recently, Hangzhou ConVerd Co., Ltd. made its debut at the 2019 Annual Meeting of the American Association for Cancer Research (AACR Annual Meeting 2019)
-
【Company News】 Promote independent scientific and technological innovation and protect intellectual property rights -- the medical bioinventory review department of Patent Examination Cooperation (Beijing) Center of the Patent Office, CNIPA2018-11-17On November 14, 2018, a group of seven people, from Patent examination Examination of the state Cooperation (Beijing) Center of the Patent Office, CNIPA， came to Hangzhou Future Sci-Tech City
-
【Company News】 Dr. Hu fang, chairman of the board, invited to attend the 6th Healthcare and Life Sciences Leadership Summit2018-11-09On Nov 1, 2018, the 6th Healthcare and Life Sciences Leadership Summit was held at the Dongjiao State Guest Hotel in Shanghai.
-
Oct. 19, 2018. Professor Michel L. Tremblay from McGill University visited Converd and had a proactive communication with our scientists.
-
【Company News】 Wu Weizhong, Director of the Institute of Liver Cancer, Zhongshan Hospital, visited Converd2018-07-05Wu Weizhong, the Director of the Institute of Liver Cancer and Deputy Director of Cell Therapy Research Center of Zhongshan Hospital affiliated to Fudan University
-
【Company News】 Nanjing Legend Biotechnology Company's Chief Strategy Officer Dr. Zhu Li visited Converd2018-07-05Dr Zhu Li, the Chief Strategy Officer of Nanjing Legend Biotechnology Co., visited Converd and had in-depth communication with Dr. Hu Fang, Chairman of Converd,
-
【Company News】 Converd’s clinical trial of using oncolytic virus in combination with immunotherapy for gastrointestinal cancers2018-04-30Converd has initiated a phase I/II clinical trial: A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer agent (A01) with Immune Cells (IC01) in patients with Advanced Gastrointestinal Cancer.
-
【Company News】 A clinical study of CAR-NK for treatment of metastatic solid tumors is conducted by Converd’s subsidiary, Hangzhou Youshan Sictech Ltd.2018-04-30This clinical study has started in the in the 3rd hospital of Guangzhou Medical University. It is designed to evaluate safety and efficacy of a novel CAR-NK cell therapy for patients with an advanced cancer.